These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 19333897

  • 1. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P, Lasters I.
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [Abstract] [Full Text] [Related]

  • 2. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates.
    De Groot AS, McMurry J, Moise L.
    Curr Opin Pharmacol; 2008 Oct; 8(5):620-6. PubMed ID: 18775515
    [Abstract] [Full Text] [Related]

  • 3. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M, Thorpe R.
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses.
    Barbosa MD, Celis E.
    Drug Discov Today; 2007 Aug; 12(15-16):674-81. PubMed ID: 17706550
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D.
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [Abstract] [Full Text] [Related]

  • 6. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS.
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [Abstract] [Full Text] [Related]

  • 7. Immunological mechanism underlying the immune response to recombinant human protein therapeutics.
    Sauerborn M, Brinks V, Jiskoot W, Schellekens H.
    Trends Pharmacol Sci; 2010 Feb; 31(2):53-9. PubMed ID: 19963283
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity of protein therapeutics.
    De Groot AS, Scott DW.
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [Abstract] [Full Text] [Related]

  • 9. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics.
    De Groot AS, Martin W.
    Clin Immunol; 2009 May; 131(2):189-201. PubMed ID: 19269256
    [Abstract] [Full Text] [Related]

  • 10. Unwanted immunogenicity: lessons learned and future challenges.
    Wadhwa M, Thorpe R.
    Bioanalysis; 2010 Jun; 2(6):1073-84. PubMed ID: 21083209
    [Abstract] [Full Text] [Related]

  • 11. Minimizing the immunogenicity of protein therapeutics.
    Chirino AJ, Ary ML, Marshall SA.
    Drug Discov Today; 2004 Jan 15; 9(2):82-90. PubMed ID: 15012932
    [Abstract] [Full Text] [Related]

  • 12. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.
    Bugelski PJ, Treacy G.
    Curr Opin Mol Ther; 2004 Feb 15; 6(1):10-6. PubMed ID: 15011776
    [Abstract] [Full Text] [Related]

  • 13. Prediction of immunogenicity for therapeutic proteins: state of the art.
    De Groot AS, Moise L.
    Curr Opin Drug Discov Devel; 2007 May 15; 10(3):332-40. PubMed ID: 17554860
    [Abstract] [Full Text] [Related]

  • 14. [Immunogenicity of therapeutic antibodies].
    Stas P, Lasters I.
    Med Sci (Paris); 2009 Dec 15; 25(12):1070-7. PubMed ID: 20035681
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity of therapeutics: a matter of efficacy and safety.
    Nechansky A, Kircheis R.
    Expert Opin Drug Discov; 2010 Nov 15; 5(11):1067-79. PubMed ID: 22827745
    [Abstract] [Full Text] [Related]

  • 16. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
    Patten PA, Schellekens H.
    Dev Biol (Basel); 2003 Nov 15; 112():81-97. PubMed ID: 12762507
    [Abstract] [Full Text] [Related]

  • 17. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C, Schnoll S, Bernstein D.
    Ann N Y Acad Sci; 2008 Oct 15; 1141():284-303. PubMed ID: 18991964
    [Abstract] [Full Text] [Related]

  • 18. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM, Grewal IS.
    Handb Exp Pharmacol; 2008 Oct 15; (181):19-44. PubMed ID: 18071940
    [Abstract] [Full Text] [Related]

  • 19. Clinical immunogenicity specificity assessments: a platform evaluation.
    Peng K, Siradze K, Quarmby V, Fischer SK.
    J Pharm Biomed Anal; 2011 Feb 20; 54(3):629-35. PubMed ID: 21035975
    [Abstract] [Full Text] [Related]

  • 20. Scientific and regulatory considerations on the immunogenicity of biologics.
    Shankar G, Shores E, Wagner C, Mire-Sluis A.
    Trends Biotechnol; 2006 Jun 20; 24(6):274-80. PubMed ID: 16631266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.